PL2714006T4 - Donosowe bio-adhezyjne formulacje żelu testosteronowego i ich zastosowanie w leczeniu hipogonadyzmu - Google Patents

Donosowe bio-adhezyjne formulacje żelu testosteronowego i ich zastosowanie w leczeniu hipogonadyzmu

Info

Publication number
PL2714006T4
PL2714006T4 PL12748245T PL12748245T PL2714006T4 PL 2714006 T4 PL2714006 T4 PL 2714006T4 PL 12748245 T PL12748245 T PL 12748245T PL 12748245 T PL12748245 T PL 12748245T PL 2714006 T4 PL2714006 T4 PL 2714006T4
Authority
PL
Poland
Prior art keywords
gel formulations
adhesive gel
treating male
intranasal testosterone
male hypogonadism
Prior art date
Application number
PL12748245T
Other languages
English (en)
Other versions
PL2714006T3 (pl
Inventor
Wayne KREPPNER
Siobhan Fogarty
Werner Oberegger
Paul José Pierre Marie Maes
Original Assignee
Acerus Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerus Biopharma Inc. filed Critical Acerus Biopharma Inc.
Publication of PL2714006T3 publication Critical patent/PL2714006T3/pl
Publication of PL2714006T4 publication Critical patent/PL2714006T4/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
PL12748245T 2011-05-15 2012-05-15 Donosowe bio-adhezyjne formulacje żelu testosteronowego i ich zastosowanie w leczeniu hipogonadyzmu PL2714006T4 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161486324P 2011-05-15 2011-05-15
US201161486634P 2011-05-16 2011-05-16
PCT/IB2012/001112 WO2012156820A1 (en) 2011-05-15 2012-05-15 Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
EP12748245.3A EP2714006B1 (en) 2011-05-15 2012-05-15 Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism

Publications (2)

Publication Number Publication Date
PL2714006T3 PL2714006T3 (pl) 2021-08-16
PL2714006T4 true PL2714006T4 (pl) 2021-08-16

Family

ID=46579248

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12748245T PL2714006T4 (pl) 2011-05-15 2012-05-15 Donosowe bio-adhezyjne formulacje żelu testosteronowego i ich zastosowanie w leczeniu hipogonadyzmu

Country Status (16)

Country Link
EP (3) EP2714006B1 (pl)
JP (9) JP6152092B2 (pl)
KR (9) KR102088038B1 (pl)
CN (4) CN103796636B (pl)
AR (2) AR089553A1 (pl)
AU (10) AU2012257492A1 (pl)
BR (2) BR112013029332A2 (pl)
CA (3) CA3034552C (pl)
DK (1) DK2714006T3 (pl)
EA (1) EA201391701A1 (pl)
ES (1) ES2859784T3 (pl)
IL (2) IL229401A0 (pl)
MX (4) MX363561B (pl)
PL (1) PL2714006T4 (pl)
WO (2) WO2012156822A1 (pl)
ZA (2) ZA201309265B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
WO2012156822A1 (en) * 2011-05-15 2012-11-22 Trimel Pharmaceuticals Corp. Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
US8971800B2 (en) * 2011-05-31 2015-03-03 Qualcomm Incorporated Methods and apparatus for improving NFC activation and data exchange reporting mechanisms
MX365818B (es) 2011-11-23 2019-05-30 Therapeuticsmd Inc Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
WO2014093818A2 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
JP6338658B2 (ja) * 2013-10-07 2018-06-06 アンタレス・ファーマ・インコーポレーテッド テストステロンの針補助ジェット注射を通じたヘマトクリット調節
JP2017513809A (ja) 2014-02-19 2017-06-01 アンタレス・ファーマ・インコーポレーテッド テストステロン組成物の針に補助されるジェット注射投与
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2951284A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
TW201636045A (zh) * 2015-01-28 2016-10-16 波美西恩製藥有限責任公司 組成物、促進或增強受試者之局部毛髮飽滿度及厚度或毛髮生長之方法、包括該組成物之套組及裝置
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
IL300437A (en) * 2016-01-07 2023-04-01 Viramal Ltd Gel preparations for administering a drug through the skin to maximize drug concentrations in the rough layer and serum and methods of using them
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
TWI790204B (zh) * 2016-06-02 2023-01-21 加拿大商阿爾宙斯製藥有限公司 鼻用大麻素組成物
JP2019517590A (ja) * 2016-06-03 2019-06-24 エム エ ペ ファルマ アクチェンゲゼルシャフト 多孔性賦形剤を含む経鼻用医薬組成物
HUE063346T2 (hu) * 2017-01-20 2024-01-28 M et P Pharma AG Nazális gyógyszerészeti készítmények légszennyezõ anyagoknak való kitettség kockázatainak csökkentésére
CN110999431B (zh) * 2017-06-17 2022-04-05 Lg电子株式会社 用于在无线通信系统中注册终端的方法及其设备
WO2019103108A1 (ja) * 2017-11-27 2019-05-31 あすか製薬株式会社 粉末経鼻投与製剤
CA3090262A1 (en) * 2018-02-02 2019-08-08 Aytu Bioscience, Inc. Methods of testosterone therapy
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
CN108771622B (zh) * 2018-07-11 2022-01-07 尹振图 一种自闭式针形滴嘴及眼药水瓶
CN113164384A (zh) 2018-10-26 2021-07-23 维拉莫有限公司 黏膜粘附性凝胶组合物
MX2021007032A (es) * 2018-12-14 2021-10-22 Acerus Biopharma Inc Derivados activos de éster de testosterona, composiciones y usos de los mismos.
CN112121049B (zh) * 2020-08-28 2022-02-01 嘉兴市第一医院 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用
JP2023550422A (ja) * 2020-11-19 2023-12-01 アコージア セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 非水性ゲル組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
DE4214953C2 (de) 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5576071A (en) 1994-11-08 1996-11-19 Micron Technology, Inc. Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds
JP2000514065A (ja) * 1997-07-03 2000-10-24 アルザ コーポレイション ドラッグデリバリーディバイスとその製造法
AU747041B2 (en) * 1997-11-10 2002-05-09 Strakan International Limited Penetration enhancing and irritation reducing systems
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10064950A1 (de) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
JP2005505587A (ja) * 2001-10-12 2005-02-24 シーエヌエス・インコーポレーテッド 含水性の点鼻ゲル及びその塗布装置
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
DK1670433T3 (da) * 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
DE60303854T2 (de) * 2003-11-11 2006-08-10 Mattern, Udo Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen
AU2005313601B2 (en) * 2004-12-09 2012-05-24 Bayer Intellectual Property Gmbh Stabilisation of glucocorticoid esters with acids
EA019214B1 (ru) * 2005-06-03 2014-02-28 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Способ лечения или профилактики заболеваний, вызванных дефицитом андрогенов у взрослых мужчин
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101099742A (zh) * 2006-07-06 2008-01-09 上海富海科申药业有限公司 能够减少皮肤刺激的睾酮凝胶制剂
AU2007304471B2 (en) 2006-10-04 2012-09-06 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
CA2623477C (en) * 2007-03-23 2011-05-31 Robert E. Dudley Compositions and method for treating pediatric hypogonadism
WO2009037813A1 (ja) * 2007-09-20 2009-03-26 Shiseido Company, Ltd. 経皮吸収製剤
EP2500062B1 (en) * 2007-11-13 2015-08-12 Curadis GmbH C-19 steroids for specific therapeutic uses
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
WO2012156822A1 (en) * 2011-05-15 2012-11-22 Trimel Pharmaceuticals Corp. Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration

Also Published As

Publication number Publication date
IL229401A0 (en) 2014-01-30
MX2020008599A (es) 2022-08-31
CA2836398A1 (en) 2012-11-22
ZA201309265B (en) 2016-01-27
AU2022202402A1 (en) 2022-05-12
EP2714006A1 (en) 2014-04-09
ES2859784T3 (es) 2021-10-04
KR20190117803A (ko) 2019-10-16
CA2836405A1 (en) 2012-11-22
PL2714006T3 (pl) 2021-08-16
DK2714006T3 (da) 2021-03-15
JP7017254B2 (ja) 2022-02-08
KR20200028503A (ko) 2020-03-16
CA2836405C (en) 2021-09-07
AU2020267162B2 (en) 2022-06-09
KR20200118228A (ko) 2020-10-14
MX2013013369A (es) 2014-10-17
JP2022105175A (ja) 2022-07-12
KR20140045400A (ko) 2014-04-16
MX2019003340A (es) 2019-07-04
AU2019203067A1 (en) 2019-05-23
CA3034552C (en) 2023-02-07
CN103813784A (zh) 2014-05-21
KR20140033408A (ko) 2014-03-18
JP6594924B2 (ja) 2019-10-23
MX2013013388A (es) 2014-09-15
IL229400A0 (en) 2014-01-30
KR20210029849A (ko) 2021-03-16
MX363561B (es) 2019-03-27
KR102088038B1 (ko) 2020-03-13
AU2020210227A1 (en) 2020-08-20
BR112013029332A2 (pt) 2021-06-01
WO2012156820A1 (en) 2012-11-22
CN103796636B (zh) 2019-04-05
EP2709588B1 (en) 2021-08-25
CN109481394A (zh) 2019-03-19
CA2836398C (en) 2021-12-14
AU2019203400A1 (en) 2019-08-01
JP2020073469A (ja) 2020-05-14
KR20210135003A (ko) 2021-11-11
CN110613679A (zh) 2019-12-27
EP3977982A1 (en) 2022-04-06
WO2012156820A9 (en) 2014-02-20
WO2012156822A1 (en) 2012-11-22
JP2021001206A (ja) 2021-01-07
JP2014515038A (ja) 2014-06-26
AR086409A1 (es) 2013-12-11
JP2022078222A (ja) 2022-05-24
EP2709588A1 (en) 2014-03-26
JP2014513716A (ja) 2014-06-05
JP6152092B2 (ja) 2017-06-28
CN109481394B (zh) 2023-05-05
BR112013029336A2 (pt) 2020-08-11
AU2012257492A1 (en) 2013-12-19
KR20190006194A (ko) 2019-01-17
AU2017203470A1 (en) 2017-06-22
AU2019201618A1 (en) 2019-04-18
ZA201309264B (en) 2015-09-30
KR20230041081A (ko) 2023-03-23
CN103796636A (zh) 2014-05-14
EA201391701A1 (ru) 2014-04-30
JP2020079257A (ja) 2020-05-28
BR112013029336B1 (pt) 2021-11-30
EP2714006B1 (en) 2020-12-09
JP2018199701A (ja) 2018-12-20
CA3034552A1 (en) 2012-11-22
AU2020267162A1 (en) 2020-12-03
AU2012257490A1 (en) 2013-12-19
AU2017204182A1 (en) 2017-07-20
AR089553A1 (es) 2014-09-03
JP2017160204A (ja) 2017-09-14
KR102568894B1 (ko) 2023-08-21

Similar Documents

Publication Publication Date Title
ZA201309265B (en) Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
HK1255929A1 (zh) 前體脂質體睾酮製劑
HK1206776A1 (en) Improved cleaning formulation and method
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
IL218020A0 (en) Devices and methods for dressing applicators
EP2647091A4 (en) SYSTEM AND METHOD FOR LASER CHARACTERIZATION
IL228557A0 (en) Solar absorbing formulations and related devices and methods
EP2558120A4 (en) METHOD AND COMPOSITION FOR INTRANASAL ADMINISTRATION
HUE044816T2 (hu) Készítmények és eljárások hajhullás kezelésére
EP2544655A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN
SI2667851T1 (sl) Formulacije testosterona
EP2575825A4 (en) COMPOSITIONS AND METHODS FOR TREATING DEPRESSION
EP2689770A4 (en) DAMAGED HAIR CARE AND METHOD FOR IMPROVING THE CONDITION OF DAMAGED HAIR THEREWITH
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
PT2608766E (pt) Processo e kit para o tratamento do cabelo
EP2732550A4 (en) BROADBAND DOHERTY AMPLIFIER WITH BROADBAND TRANSFORMER
IL229322A0 (en) Low strength testosterone intranasal gel preparations and their use for the treatment of anorgasmia or libido disorder
GB2490787B (en) Compact broadband source and method
HK1198137A1 (en) Disinfecting formulations and uses thereof
EP2557720A4 (en) DEVICE AND METHOD FOR TRANSFORMATION
EP2822578A4 (en) TISSUE CONSTRUCTS AND USES THEREOF
ZA201207226B (en) Compositions and methods for treating viral diseases
ZA201409029B (en) Cosmetic composition and method for using thereof
ZA201409028B (en) Cosmetic composition and method for using thereof
EP2776462A4 (en) INDOLALKYLAMINO WITHASTEROID CONJUGATES AND USE METHOD THEREFOR